Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
Bildiriler > Özet Bildiri · 2020
Yazarlar: M. Md Yusof, D. W. Cescon, H. S. Rugo, S-A. Im, C. Gallardo, O. Lipatov, C. H. Barrios, E. Holgado, H. Iwata, N. Masuda, Erhan GÖKMEN, S. Loi, Z. Guo, E. Jensen, G. Aktan, V. Karantza, P. Schmid, J. Cortes
ESMO Asia Virtual Congress, ELECTR NETWORK, Uluslararası, Sözlü Sunum, Özet Bildiri, 2020-2020, Wos, cilt 31, ss S1257-S1257